Thanks for the words Robert.
I wish there were better long-range ADR studies, esp. w/regard to the facet problems we're hearing here, etc. Also, each study should incorporate how many ADRs a doc has done in the matrix w/other variables. I kinda think that Johnson and Johnson partially screwed the pooch by having such high mark-ups with Charite's (e.g. $11K extra vs. Europe). I'm meandering: I partially blame the insurance problems in that the Europeans have had such lousy data imo.
Regardless, I wish you well in your decision and recovery in your Thailand pad.
